Spots Global Cancer Trial Database for small lymphocytic lymphoma
Every month we try and update this database with for small lymphocytic lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | NCT00759603 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | NCT02258529 | Follicular Lymp... Small Lymphocyt... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | NCT03263637 | Relapsed or Ref... Acute Myeloid L... Acute Lymphocyt... Chronic Lymphoc... High Risk Myelo... Chronic Myelomo... Richter's Syndr... B-cell Non-Hodg... T-cell Non-Hodg... Small Lymphocyt... Multiple Myelom... | AZD4573 | 18 Years - 130 Years | AstraZeneca | |
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | NCT05959694 | Chronic Lymphoc... Small Lymphocyt... | TQB3909 tablet | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL | NCT01217749 | B-cell Chronic ... Small Lymphocyt... Prolymphocyctic... Richter's Trans... | PCI-32765 ofatumumab | 18 Years - | Pharmacyclics LLC. | |
| Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00290004 | Chronic Lymphoc... Small Lymphocyt... Leukemia Lymphoma | motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT02406742 | Leukemia, Lymph... | CC-122 Ibrutinib Obinutuzumab | 18 Years - 79 Years | Celgene | |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | NCT02529813 | Acute Biphenoty... Acute Lymphobla... Blasts 5 Percen... CD19 Positive Minimal Residua... Non-Hodgkin Lym... Small Lymphocyt... Stage III Chron... Stage IV Chroni... | Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Tisagenlecleuce... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | NCT04504708 | Non-hodgkin Lym... Chronic Lymphoc... Small Lymphocyt... | ZX-101A | 18 Years - | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | |
| ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | NCT02029443 | Chronic Lymphoc... Small Lymphocyt... Richter's Syndr... Prolymphocytic ... | Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01611090 | Chronic Lymphoc... Small Lymphocyt... | Ibrutinib Bendamustine hy... Rituximab Placebo | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant | NCT02118311 | Hematologic Mal... | T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra... | 18 Years - 69 Years | Masonic Cancer Center, University of Minnesota | |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | NCT03801525 | Chronic Lymphoc... Small Lymphocyt... | Ublituximab Umbralisib Venetoclax | 18 Years - | TG Therapeutics, Inc. | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732926 | Indolent Non-Ho... | Idelalisib Rituximab Bendamustine Placebo | 18 Years - | Gilead Sciences | |
| Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | NCT04505254 | Chronic Lymphoc... Small Lymphocyt... | Acalabrutinib Obinutuzumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma | NCT01317901 | B-cell Small Ly... | TRU-016 Bendamustine Rituximab | 18 Years - 99 Years | Aptevo Therapeutics | |
| Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma | NCT00278161 | Leukemia Lymphoma | Pegfilgrastim Rituximab Cyclophosphamid... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | NCT01419691 | Chronic Lymphoc... Small Lymphocyt... Leukemia, Proly... | auranofin | 18 Years - | University of Kansas Medical Center | |
| Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia | NCT05417165 | Chronic Lymphoc... Small Lymphocyt... | Pneumococcal 20... Pneumococcal Po... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Safe Accelerated Venetoclax Escalation in CLL | NCT04843904 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Obinutuzumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Safe Accelerated Venetoclax Escalation in CLL | NCT04843904 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Obinutuzumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | NCT02238522 | Lymphoprolifera... Acute Myeloid L... | ZEN003365 | 18 Years - | Zenith Epigenetics | |
| Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT04852822 | Chronic Lymphoc... Small Lymphocyt... | Biospecimen Col... Electronic Heal... | 18 Years - | University of Washington | |
| A Study Of The Selective PKC-β Inhibitor MS- 553 | NCT03492125 | Chronic Lymphoc... Small Lymphocyt... Aggressive Lymp... | MS-553 MS-553 acalabrutinib venetoclax Rituximab obinutuzumab | 18 Years - | MingSight Pharmaceuticals, Inc | |
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | NCT01161511 | Chronic Lymphoc... Small Lymphocyt... | XmAb5574 | 18 Years - | Xencor, Inc. | |
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | NCT02238522 | Lymphoprolifera... Acute Myeloid L... | ZEN003365 | 18 Years - | Zenith Epigenetics | |
| Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02518555 | Chronic Lymphoc... Small Lymphocyt... | Diphtheria Toxo... Ibrutinib Laboratory Biom... Pharmacological... Pneumococcal 13... Quality-of-Life... Trivalent Influ... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02048813 | Anemia Chronic Lymphoc... Small Lymphocyt... | Cyclophosphamid... Fludarabine Pho... Ibrutinib Laboratory Biom... Pharmacogenomic... Quality-of-Life... Rituximab | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | NCT02877082 | Acute Leukemia Chronic Lymphoc... Chronic Myeloge... Diffuse Large B... Follicular Lymp... Graft Versus Ho... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Myeloproliferat... Small Lymphocyt... | Thymoglobulin Bortezomib Tacrolimus | 18 Years - 75 Years | Emory University | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732913 | Indolent Non-Ho... | Placebo Rituximab Idelalisib | 18 Years - | Gilead Sciences | |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | NCT03801525 | Chronic Lymphoc... Small Lymphocyt... | Ublituximab Umbralisib Venetoclax | 18 Years - | TG Therapeutics, Inc. | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis | NCT00132015 | Chronic Myelopr... Leukemia Lymphoma Nonneoplastic C... Precancerous Co... | tanespimycin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | NCT04030195 | Non-Hodgkin's L... Chronic Lymphoi... Non-Hodgkin's L... Chronic Lymphoc... Lymphoma, Non-H... Leukemia, Lymph... B-cell Chronic ... B-cell Non Hodg... Small Lymphocyt... | PBCAR20A Fludarabine Cyclophosphamid... | 18 Years - | Precision BioSciences, Inc. | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) | NCT00364286 | Leukemia Lymphoma | Dasatinib (BMS-... | - | M.D. Anderson Cancer Center | |
| Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: | NCT05371808 | Chronic Lymphoc... Small Lymphocyt... | EQ-5D-5L Instru... Work Productivi... Resource Utiliz... | 18 Years - | Canadian Cancer Trials Group | |
| Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT01744626 | Leukemia Lympho... | CC-292 Rituximab | 18 Years - | Celgene Corporation | |
| Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | NCT00850057 | Chronic Lymphoc... Small Lymphocyt... | Intranodal inje... | 18 Years - | University of California, San Diego | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | NCT06136559 | Chronic Lymphoc... Small Lymphocyt... | Nemtabrutinib Ibrutinib Acalabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | NCT00201682 | Chronic Lymphoc... Small Lymphocyt... | Etanercept Rituximab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | NCT03410901 | B-Cell Non-Hodg... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... | Anti-OX40 Antib... Laboratory Biom... Radiation Thera... TLR9 Agonist SD... | 18 Years - | Stanford University | |
| Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT04852822 | Chronic Lymphoc... Small Lymphocyt... | Biospecimen Col... Electronic Heal... | 18 Years - | University of Washington | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | NCT03410901 | B-Cell Non-Hodg... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... | Anti-OX40 Antib... Laboratory Biom... Radiation Thera... TLR9 Agonist SD... | 18 Years - | Stanford University | |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | NCT01239875 | Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Adult Diffuse M... Adult Diffuse S... Adult Grade III... Adult Immunobla... Adult Lymphobla... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Splenic Margina... Waldenstrom Mac... | dendritic cell ... cryotherapy pneumococcal po... laboratory biom... immunoenzyme te... immunohistochem... autologous dend... | 18 Years - 90 Years | Mayo Clinic | |
| Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | NCT05317936 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | NCT01282424 | Follicular Lymp... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT02623920 | Diffuse Large B... Mediastinal Lar... Grey Zone Lymph... High Grade B Ce... Follicular Lymp... Marginal Zone L... Small Lymphocyt... | Brentuximab Bendamustine Rituximab | 18 Years - | University of Arizona | |
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | NCT01161511 | Chronic Lymphoc... Small Lymphocyt... | XmAb5574 | 18 Years - | Xencor, Inc. | |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02048813 | Anemia Chronic Lymphoc... Small Lymphocyt... | Cyclophosphamid... Fludarabine Pho... Ibrutinib Laboratory Biom... Pharmacogenomic... Quality-of-Life... Rituximab | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | NCT01239875 | Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Adult Diffuse M... Adult Diffuse S... Adult Grade III... Adult Immunobla... Adult Lymphobla... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Splenic Margina... Waldenstrom Mac... | dendritic cell ... cryotherapy pneumococcal po... laboratory biom... immunoenzyme te... immunohistochem... autologous dend... | 18 Years - 90 Years | Mayo Clinic | |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760 | Lymphoma B-cell Lymphoma | Leukapheresis Stem Cell Trans... CD19-specific T... IL-2 Carmustine Etoposide Cytarabine Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) | NCT01253460 | Leukemia | Cyclophosphamid... Rituximab Sapacitabine | 18 Years - | M.D. Anderson Cancer Center | |
| T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | NCT00602693 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | umbilical cord ... Allopurinol fludarabine pho... Cyclophosphamid... Total body irra... Treg infusion Sirolimus | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | NCT03701282 | Chronic Lymphoc... Small Lymphocyt... | Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Ibrutinib Obinutuzumab Quality-of-Life... Venetoclax | 18 Years - 69 Years | National Cancer Institute (NCI) | |
| Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | NCT01728207 | Non-hodgkin's L... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... | IMMU-114 | 18 Years - | Gilead Sciences | |
| PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | NCT01131247 | Chronic Lymphoc... | ofatumumab + be... | 18 Years - | Nevada Cancer Institute | |
| Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma | NCT01239394 | Follicular Lymp... Marginal Zone L... Small Lymphocyt... | ofatumumab | 18 Years - | Massachusetts General Hospital | |
| A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | NCT01650727 | Chronic Lymphoc... Small Lymphocyt... | Dinaciclib Rituximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | NCT03737981 | Chronic Lymphoc... Small Lymphocyt... | Ibrutinib Obinutuzumab Observation Venetoclax | 65 Years - | National Cancer Institute (NCI) | |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | NCT02529813 | Acute Biphenoty... Acute Lymphobla... Blasts 5 Percen... CD19 Positive Minimal Residua... Non-Hodgkin Lym... Small Lymphocyt... Stage III Chron... Stage IV Chroni... | Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Tisagenlecleuce... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | NCT02339922 | Chronic Lymphoc... Follicular Lymp... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Extra... Refractory Extr... Small Lymphocyt... Waldenstrom Mac... | Ixazomib Citrat... Laboratory Biom... Rituximab | 18 Years - | University of Washington | |
| A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT06291220 | Chronic Lymphoc... Small Lymphocyt... | Obinutuzumab ABBV-453 | 18 Years - | AbbVie | |
| A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | NCT03406156 | Chronic Lymphoc... Small Lymphocyt... | Obinutuzumab Bendamustine Venetoclax | 18 Years - 99 Years | AbbVie | |
| Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia | NCT01013961 | Chronic Lymphoc... | alemtuzumab rituximab | 65 Years - | Eastern Cooperative Oncology Group | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia | NCT00234481 | Chronic Lymphoc... Small Lymphocyt... | XL844 | 18 Years - | Exelixis | |
| A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | NCT01650727 | Chronic Lymphoc... Small Lymphocyt... | Dinaciclib Rituximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL | NCT01400685 | Chronic Lymphoc... Small Lymphocyt... B Chronic Lymph... | Lenalidomide Bendamustine Rituximab | 18 Years - 80 Years | Massachusetts General Hospital | |
| BR in Patients With CLL With Comorbidities and/or Renal Dysfunction | NCT01832922 | Chronic Lymphoc... Small Lymphocyt... | Bendamustine Rituximab | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | NCT04763083 | Chronic Lymphoc... Small Lymphocyt... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non-small Cell ... Malignant Melan... | NVG-111 | 18 Years - | NovalGen Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
